CN102920723A - New application of Ginsenoside Rb1 in aspect of in vivo antihypertension - Google Patents
New application of Ginsenoside Rb1 in aspect of in vivo antihypertension Download PDFInfo
- Publication number
- CN102920723A CN102920723A CN 201210486959 CN201210486959A CN102920723A CN 102920723 A CN102920723 A CN 102920723A CN 201210486959 CN201210486959 CN 201210486959 CN 201210486959 A CN201210486959 A CN 201210486959A CN 102920723 A CN102920723 A CN 102920723A
- Authority
- CN
- China
- Prior art keywords
- ginsenoside
- antihypertension
- vivo
- new application
- blood pressure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of biological medicine, and relates to a new application of traditional Chinese medicine extract Ginsenoside Rb1 in the aspect of in vivo antihypertension and also describes a pharmaceutical composition which contains the Ginsenoside Rb1 and is used for preventing and treating hypertension.
Description
Technical field
The invention belongs to biomedicine field, relate to the new purposes of antihypertensive function in ginsenoside Rb1's body.
Background technology
Hypertension (hypertensive disease) is a kind of chronic disease take the lasting rising of arteriotony as main manifestations, often cause the pathological changes of the vitals such as the heart, brain, kidney and corresponding consequence occurs, hypertension belongs to " headache ", " dizzy " category of the traditional Chinese medical science.The blood pressure standard that World Health Organization's suggestion is used is: the normal adult systolic pressure should be less than or equal to 140 mmHg, and diastolic pressure is less than or equal to 90 mmHg; Systolic pressure is between 141-159 mmHg, and diastolic pressure is borderline hypertension between 91-94 mmHg.
Doctor trained in Western medicine is emphasized individualized treatment, and the traditional Chinese medical science is then paid attention to determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs.Western medicine hypertension adopts the index treatment, often too is concerned about an index of hypertension therapeutic, i.e. blood pressure values index, and under treatment-resistant, it is normal to seem the blood pressure index, in fact easily repeatedly.On theory of Chinese medical science, Chinese medicine because row neutralization, in just, the road of middle row, in hypertensive control, the conditioning viscera function is prevented and treated complication, and its relatively unique " treating both the principal and secondary aspects of a disease " advantage is arranged.Treatment by Chinese herbs mainly is environment in the blood disorderly in adjusting body, repairs impaired blood vessel wall, improves oxygen content, recovers injured cranial nerve cell, the adjustment vital organs of the human body, and qi blood balance, dredging the meridian reaches equilibrium between yin and yang.Common blood pressure lowering Chinese patent medicine has An ' gong blood pressure-reducing ball, Chinese hawthorn blood-pressure-reducing capsule, compound recipe antelope angle hypertension pill, chiang ya wan, chrysanthemum publicly price-reduction tabletting, Bezoar pill for lowering blood pressure etc.; Common Chinese hypotensor has Ramulus Uncariae Cum Uncis, Folium Apocyni Veneti, Radix Puerariae, the Radix Astragali etc.
Summary of the invention
The object of the present invention is to provide the new purposes of ginsenoside Rb1 in resisting hypertension.
Further, be used for preventing and treating the hypertensive ginsenoside Rb1's of containing pharmaceutical composition.
The ginsenoside Rb1 can effectively reduce blood pressure, and controls preferably the systolic pressure of spontaneous hypertensive rat (SHR).
The medicine that the present invention prevents and treats the hypertensive ginsenoside Rb1 of containing also contains the pharmaceutics acceptable carrier, comprises excipient and adjuvant, and dosage form can be the dosage form on any pharmaceutics.
The specific embodiment
The embodiment 1. ginsenoside Rb1s activity that reduces blood pressure
The ginsenoside Rb1 is available from Shenyang Long Pu Science and Technology Ltd. in the present embodiment, and purity is 98%.
10～12 week spontaneous hypertensive rats in age (SHR) are pressed the blood pressure grouping, and concrete dosage sees Table 1, and administration is the arteria caudalis pressure measurement after 7 days.
Statistical analysis: measurement data mean+SD
Expression, t check between relatively employing group of data between two groups.Take P＜0.05 as the significance standard.
The result: the ginsenoside Rb1 can effectively reduce the SHR rat blood pressure, and relatively there were significant differences (P＜0.05) with model control group, sees Table 1.
Table 1. ginsenoside Rb1 successive administration is on the impact of SHR rat blood pressure
Compare with model control group
△P＜0.05.
Claims (2)
1. the new purposes of a Chinese medicine extract is characterized in that: the new purposes of antihypertensive function in ginsenoside Rb1's body.
2. the new purposes of a kind of Chinese medicine extract according to claim 1 is characterized in that: the pharmaceutical composition that is used for preventing and treating the hypertensive ginsenoside Rb1 of containing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210486959 CN102920723A (en) | 2012-11-26 | 2012-11-26 | New application of Ginsenoside Rb1 in aspect of in vivo antihypertension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210486959 CN102920723A (en) | 2012-11-26 | 2012-11-26 | New application of Ginsenoside Rb1 in aspect of in vivo antihypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102920723A true CN102920723A (en) | 2013-02-13 |
Family
ID=47635748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210486959 Pending CN102920723A (en) | 2012-11-26 | 2012-11-26 | New application of Ginsenoside Rb1 in aspect of in vivo antihypertension |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102920723A (en) |
-
2012
- 2012-11-26 CN CN 201210486959 patent/CN102920723A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101822789B (en) | Hypotensor treating essential hypertension | |
| CN102526276B (en) | Anti-hypertension medicinal composition and preparation method for same | |
| CN102920815A (en) | Application of active parts of gambir plant total alkaloids | |
| CN1698804A (en) | Chinese medicinal preparation for treating qi obstruction in chest and heart palpitation and its preparation process | |
| CN103735622A (en) | Primary hypertension resistance medicine | |
| CN103735881A (en) | Compound preparation | |
| CN1839999A (en) | Preparation for treating osteoporosis and preparation method thereof | |
| CN102657828A (en) | Pharmaceutical composition for treating chronic heart failure | |
| CN102920723A (en) | New application of Ginsenoside Rb1 in aspect of in vivo antihypertension | |
| CN102920724A (en) | New application of Ginsenoside Re in aspect of in vivo antihypertension | |
| CN102920725A (en) | New application of traditional Chinese medicine extract | |
| CN102961369A (en) | New medicinal application of curdione | |
| CN101584789A (en) | Chinese medicament for treating hypomenorrhea and amenorrhea | |
| CN101361797B (en) | Traditional Chinese medicine pressure-reduction insoles | |
| CN1311847C (en) | Hypertension treating medicine | |
| CN103599394A (en) | Traditional Chinese medicine for treating hypertension | |
| CN104940516A (en) | Traditional Chinese medicine composition for treating chronic aplastic anemia, and preparation method and application thereof | |
| CN103800675A (en) | Traditional Chinese medicine for treating hypertension and preparation method of traditional Chinese medicine | |
| CN103272122A (en) | Traditional Chinese medicinal composition for treating Chronic aplastic anemia | |
| CN102727664A (en) | Chinese herbal preparation for treating thrombocytopenia | |
| CN102512624B (en) | Chinese medicine soup with functions of dispelling flatulence and strengthening stomach for treating functional dyspepsia | |
| CN100540043C (en) | A kind of treatment hypertension drug | |
| CN102319387A (en) | Traditional Chinese medicine composition for treating chronic cough | |
| CN103751270A (en) | Compound antihypertensive preparation | |
| CN103735882A (en) | Preparation containing panax notoginseng |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130213 |